SGLT2 inhibitors directly affect cardiomyocytes by inhibiting Na+/H+ exchanger activity and suppressing late Na+ currents.Meta-analysis of trials shows a reduced risk of SCD in HF patients treated with SGLT2 inhibitors, with varying effects in those with reduced ejection fraction. This evidence concerns the gene SLC5A2 and Schnyder corneal dystrophy.